A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...
Kronos is cutting 83% of its workforce, while Idorsia is considering cutting as many as 270 jobs. Elsewhere, PTC disclosed ...
Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...
Bio-Techne Corporation today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Citi 2024 Global Healthcare Conference on Wednesday, December 4, 2024, at 3:15 p.m ...
Leerink Partners analyst Mani Foroohar has maintained their neutral stance on ALNY stock, giving a Hold rating on November 25.Don't Miss our ...
Algert Global LLC increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 401.3% ...
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) – Investment analysts at Zacks Research increased their FY2024 ...
Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) yesterday and set a price target of ...
ALNY reports submitting an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.
DelveInsight’s “Hemophilia B Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding ...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company’s ...
Delving into the details, we found 5% of traders were bullish, while 84% showed bearish tendencies. Out of all the trades we spotted, 14 were puts, with a value of $931,387, and 5 were calls, valued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback